Trial reportScientific reports2026
Microfluidic sperm selection versus density gradient centrifugation in ICSI cycles with abnormal semen parameters: a randomized sibling-oocyte study.
Trial report in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Microfluidic sperm selection (MSS) is a centrifugation-free alternative to density gradient centrifugation (DGC) for sperm preparation in intracytoplasmic sperm injection (ICSI). This prospective, randomized sibling-oocyte study included 55 ICSI cycles from 55 couples treated between February 2025 and February 2026. Eligible couples had abnormal semen parameters according to World Health Organization 2021 criteria. Within each cycle, sibling metaphase II oocytes were randomly allocated to ICSI using sperm prepared by MSS or DGC. The primary outcome was blastocyst formation per two-pronuclear embryo (2PN). Secondary outcomes included fertilization, cleavage, good-quality blastocyst rate, and euploidy rate. Embryo-level outcomes were analyzed using a mixed-effects binomial regression model. MSS was associated with a higher fertilization rate than DGC (82.3% vs. 74.7%; OR 1.60, 95% CI 1.07-2.39; p = 0.022). Cleavage, blastocyst formation (61.8% vs. 65.2%; p = 0.494), and good-quality blastocyst rates were similar between groups. Among 47 cycles undergoing preimplantation genetic testing for aneuploidy, euploidy rates per biopsied blastocyst did not differ significantly between the MSS and DGC groups. Overall, MSS was associated with higher fertilization, while subsequent embryologic outcomes were comparable between groups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.